Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
Alto Neuroscience, Inc.
ANRO · SEC Filings
website
68
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing i...
Price
27.8
Market Cap
1.09 B
Float
35.55 M
Country
US
Sector
Healthcare
Exchange
NYSE
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about ANRO
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
Alto Neuroscience, Inc.
ANRO · SEC Filings
35.55 M
Float
27.8
Price
1.09 B
Market Cap
Financials
TYPE
HEADLINE
FILED AT
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 12, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 13, 2026
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 16, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 12, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 13, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 14, 2025
News
TYPE
HEADLINE
FILED AT
8-K
Alto Neuroscience Promotes Nicholas C. Smith to President and Chief Financial Officer
Aug 27, 2026
8-K
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Expands ALTO-207 Development Program
Aug 12, 2026
8-K
Alto Neuroscience, Inc. Announces Underwritten Registered Direct Offering of Common Stock
Jul 14, 2026
8-K
Alto Neuroscience Reports Preliminary Cash Position and Pipeline Expansion for ALTO-207
Jul 13, 2026
8-K
Alto Neuroscience, Inc. Appoints Andrew Miller, Ph.D. to Board of Directors
May 28, 2026
8-K
Alto Neuroscience, Inc. Announces Results of 2026 Annual Meeting of Stockholders
May 13, 2026
Prospectus
TYPE
HEADLINE
FILED AT
424B5
REGISTERED OFFERING
Jul 14, 2026
424B4
OFFERING | Shares amount: 8,040,000 | Share price: $16.00 | Offering amount: $128,640,000.00
Feb 5, 2024
Registrations
TYPE
HEADLINE
FILED AT
S-3
SHARE RESALE REGISTRATION
Apr 10, 2026
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Mar 16, 2026
S-3
SHARE RESALE REGISTRATION
Nov 26, 2025
D
Form D - Notice of Exempt Offering of Securities - Item 06b
Oct 27, 2025
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Mar 20, 2025
S-3
Form S-3 - Registration statement under Securities Act of 1933
Feb 3, 2025
Proxies
TYPE
HEADLINE
FILED AT
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 26, 2026
DEF 14A
Form DEF 14A - Other definitive proxy statements
Mar 26, 2026
DEFR14A
Form DEFR14A - Revised definitive proxy soliciting materials
May 9, 2025
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 1, 2025
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 1, 2025
Ownerships
TYPE
HEADLINE
FILED AT
SCHEDULE 13G
VANGUARD CAPITAL MANAGEMENT LLC (Filed by)
Oct 30, 2026
4
Smith Nicholas Conrad (Reporting)
Oct 5, 2026
4
Smith Nicholas Conrad (Reporting)
Oct 1, 2026
144
Form 144 - Report of proposed sale of securities
Sep 29, 2026
SCHEDULE 13G/A
PERCEPTIVE ADVISORS LLC (Filed by)
Aug 14, 2026
SCHEDULE 13G/A
Vestal Point Capital, LP (Filed by)
Aug 14, 2026
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
EFFECT
Form EFFECT - Notice of Effectiveness
Apr 21, 2026
CORRESP
Form CORRESP - Correspondence
Apr 17, 2026
LETTER
Form UPLOAD - SEC-generated letter
Apr 16, 2026
EFFECT
Form EFFECT - Notice of Effectiveness
Dec 11, 2025
CORRESP
Form CORRESP - Correspondence
Dec 8, 2025
EFFECT
Form EFFECT - Notice of Effectiveness
Feb 12, 2025
